title: Blockade of central angiotensin II does not affect the reduction in renal sympathetic nerve activity following a volume load in heart failure rabbits.
abstract: 1. We investigated the role in sympathetic nerve regulation of endogenous angiotensin (Ang)II in the brain in heart failure by examining the effect of losartan on the resting mean arterial blood pressure (MAP), heart rate (HR) and renal sympathetic nerve activity (RSNA) and the reflex reduction in RSNA elicited by acute volume expansion in conscious rabbits. 2. Heart failure was induced with doxorubicin (1 mg/kg, i.v., twice weekly for 6 weeks). On the experimental day, MAP, HR and RSNA were recorded in conscious rabbits before and after losartan (10 microg; n = 6) or Ringer's (control; n = 5) injected in the fourth brain ventricle. Animals were then administered an acute volume load with the plasma expander Haemaccel (Hoechst Marion Roussel, Lane Cove, NSW, Australia; 2 mL/min, i.v., for 30 min). 3. Losartan did not significantly affect the resting basal levels of MAP, HR and RSNA. There was no significant difference between losartan- and Ringer's-treated animals. 4. Volume expansion in the control group elicited a significant reduction of 40% in RSNA. In the losartan-treated group, a similar reduction (42%) was observed. There was no significant difference between the treatments. The administration of losartan did not significantly affect MAP and HR during volume expansion compared with the control group. 5. We conclude that AngII in the brainstem does not play a major role in the maintenance of resting MAP, HR and RSNA or in the reflex reduction in RSNA elicited by volume expansion in the conscious rabbit with doxorubicin-induced heart failure.
authors.affiliation: Department of Medicine, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. emilio.badoer@rmit.edu.au
authors.forename: E
authors.initials: E
authors.lastname: Badoer
authors.forename: B P
authors.initials: BP
authors.lastname: McGrath
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D000903:Antibiotics, Antineoplastic; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume / Q000502:physiology; D004317:Doxorubicin; D004566:Electrodes; D006333:Heart Failure / Q000139:chemically induced / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular; D007668:Kidney / Q000187:drug effects / Q000294:innervation*; D019808:Losartan / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D011817:Rabbits; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
chemical_list: D000903:Antibiotics, Antineoplastic; D000804:Angiotensin II; D004317:Doxorubicin; D019808:Losartan